Pivotal has announced the acquisition of Akcelis BVBA, a full-service provider of patient enrollment and retention solutions for clinical trials in the life sciences industry.
Patient recruitment is a well-known bottleneck in clinical trials as Sponsors can experience challenges across many therapeutic areas. United by a common culture, Akcelis brings experience to Pivotal to recruit and retain a patient population for difficult-to-recruit trials.
“This acquisition fits perfectly with our commitment to bringing innovation to the clinical development process to deliver efficiencies for our clients,” said Lidia Farr, VP Corporate Development and Finance at Pivotal. “Akcelis will bring advanced, proprietary and analytics-driven technology and services to customize the most efficient and cost-effective approach to significantly improve site selection and patient enrollment and retention strategies for our clients´ clinical trials. As we focus on delivering this value for our customers, we are pleased to welcome our new colleagues to Pivotal to become part of our solution-oriented culture and help advance drug development to improve patient lives.”
Providing analytics-driven services to many large and mid-sized pharmaceutical companies, Akcelis manages the entire patient recruitment lifecycle, from recruitment to enrollment to retention. These services utilize innovative, proprietary, and predictive software analytics to customize an efficient and effective approach to recruiting patients for a customer's clinical trial.
“Pivotal’s expertise in clinical research and Akcelis’ patient-centric approach to accelerate patient recruitment are the winning combination for scientifically elegant and patient-friendly clinical trials,” said Barbara D’haene and Nathalie Niclaus, Akcelis Managing Directors and Founders. “We look forward to positively impacting Pivotal’s clinical research excellence by implementing innovative digital patient recruitment strategies.”